Company intelligence / Profile preview

SixPeaks Bio AG

Basel, Basel-Stadt, Switzerlandsixpeaksbio.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Preclinical studies of the lead molecules show improved potency, biophysical properties, and pharmacokinetics/pharmacodynamics, as well as reduced off-target binding compared with competing antibodies. In both lean and obese mouse models, SixPeaks' lead molecules show potentially best-in-class efficacy for muscle mass preservation both as a single agent and when combined with GLP-1 agonists[2].

Therapeutic areas: Metabolic DisordersEndocrinologyCardiovascular
Modalities: AntibodiesmAb-peptide conjugatesbispecific antibodies
Industry: Biotech

Drug pipeline

4 assets

ActR2A/B GLP1 conjugate

Preclinical

3 more assets in the full pipeline.

Request access →

Partnerships

AstraZeneca (strategic collaboration with option to acquire)

Beyond the preview

Go deeper on SixPeaks Bio AG.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SixPeaks Bio AG.

Explore the full profile